GC Biopharma’s Hunter Syndrome Treatment ‘Hunterase’ Receives Drug Approval in India and Taiwan

  • Post author:
  • Post category:Sales & Growth

- Secures approval for 'Hunterase IV' in India and both 'Hunterase IV & ICV' in Taiwan, accelerating expansion into the Asian rare disease market YONGIN, South Korea, Aug. 24, 2026 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global…

Continue ReadingGC Biopharma’s Hunter Syndrome Treatment ‘Hunterase’ Receives Drug Approval in India and Taiwan

LONGi at UNCCD COP17: Li Zhenguo Explains Two Technological Pathways for PV-Powered Food Security

ULAANBAATAR, Mongolia, Aug. 23, 2026 /PRNewswire/ -- From August 17 to 28, 2026, the 17th session of the Conference of the Parties to the United Nations Convention to Combat Desertification (UNCCD COP17) is being held in Ulaanbaatar, Mongolia.…

Continue ReadingLONGi at UNCCD COP17: Li Zhenguo Explains Two Technological Pathways for PV-Powered Food Security

Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics

  • Post author:
  • Post category:Sales & Growth

SEONGNAM, South Korea, Aug. 23, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Lilly Gateway Labs is…

Continue ReadingRznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics

Consortium launches cross-regional pilot on post-quantum security with participation from banks and regulatory stakeholders

Convened by the Responsible Fintech Institute with Safeheron as technology partner, to evaluate and eventually open-source quantum-resilient infrastructure for wallet generation and digital asset transfers in a regulated, cross-jurisdiction setting. SINGAPORE, Aug. 23, 2026 /PRNewswire/ -- The Responsible…

Continue ReadingConsortium launches cross-regional pilot on post-quantum security with participation from banks and regulatory stakeholders

Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion

  • Post author:
  • Post category:Sales & Growth

TAIPEI, Aug. 23, 2026 /PRNewswire/ -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate…

Continue ReadingAnbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion